Blog

Brivaracetam (BRV) is a high-affinity synaptic vesicle glycoprotein 2A ligand (SV2A) that is currently licensed as monotherapy or adjunctive therapy for the treatment of focal-onset seizures in people with epilepsy aged ≥ 4 years [1]. After oral administration, BRV is rapidly and completely absorbed; it has low (< 20%) plasma protein binding and a linear and predictable pharmacokinetic profile [2]; furthermore, it carries low risks of drug–drug interactions [3]. Recently, BRV has gained interest for its use in emergency situation such as acute repetitive seizure and status epilepticus (SE).